Showing 1911-1920 of 2657 results for "".
- OneSight EssilorLuxottica Foundation Partners with WHO on SPECS 2030 Initiativehttps://modernod.com/news/onesight-essilorluxottica-foundation-partners-with-who-on-specs-2030-initiative-1/2482570/The OneSight EssilorLuxottica Foundation has announced a collaboration with the World Health Organization (WHO) as a global partner in the SPECS 2030 initiative. This strategic alliance is set to accelerate progress toward the world’s first global target for effective refractive error cover
- Outlook Therapeutics Receives NICE Recommendation of Lytenava for Wet AMDhttps://modernod.com/news/outlook-therapeutics-receives-nice-recommendation-for-lytenava-as-a-treatment-for-wet-amd/2482567/The UK’s National Institute for Health and Care Excellence (NICE) has recommended Lytenava (bevacizumab gamma) as an option for the treatment of wet AMD in adults. This marks the first positive reimbursement decision for Lytenava worldwide and supports its commercializat
- Galimedix Begins Phase 1 Clinical Trial of Oral GAL-101 for Neuroprotective Treatmenthttps://modernod.com/news/galimedix-therapeutics-begins-phase-1-clinical-trial-of-oral-gal-101-for-neuroprotective-treatment/2482565/Galimedix Therapeutics announced the first volunteers have been dosed in the company’s phase 1 study of oral GAL-101, an amyloid beta (Aβ) aggregation modulator. This trial is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses
- Johnson & Johnson Appoints Shawn Millerick President, Vision Care, Americashttps://modernod.com/news/johnson-johnson-appoints-shawn-millerick-president-vision-care-americas/2482556/Johnson & Johnsonhas announced the appointment of Shawn Millerick as President, Vision Care, Americas, effective November 11, 2024. Mr. Millerick will be responsible for defining strategy and driving growth for Johnson & Johnson’s Vision Care portfolio in North Americ
- Atsena and Nippon Shinyaku Enter Strategic Collaboration for ATSN-101 Advancementhttps://modernod.com/news/atsena-therapeutics-and-nippon-shinyaku-enter-strategic-collaboration-for-atsn-101-advancement/2482542/Atsena Therapeutics has entered into an exclusive licensing agreement with Nippon Shinyaku for the commercialization of investigational gene therapy ATSN-101 for Leber congenital amaurosis. Atsena's ATSN-101 is a subretinal AAV5 gene therapy undergoing evaluatio
- Bausch + Lomb’s Recycling Programs Collect Over 94 Million Units of Eye Care Waste in the UShttps://modernod.com/news/bausch-lombs-recycling-programs-collect-over-94-million-units-of-eye-care-waste-in-the-us/2482541/Bausch + Lomb announced a milestone in its sustainability efforts—the company's exclusive recycling initiatives, ONE by ONE Recycling and Biotrue Eye Care Recycling programs, have successfully collected a total of 94,119,275 units of used contact lenses, eye care, and lens care material
- Harrow Secures Medicare Part D Market Access for Vevyehttps://modernod.com/news/harrow-secures-medicare-part-d-market-access-for-vevye/2482535/Harrow announced that beginning January 1, 2025, Harrow’s dry eye disease treatment, Vevye, will be included in the formularies of major plan sponsors, including Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark. Collectively, these plan sponsors provide coverage for more tha
- Harrow Partners with Asembia to Create Digital Services and Hub Support for Harrow’s Branded Eye Care Productshttps://modernod.com/news/harrow-partners-with-asembia-to-enhance-provider-and-patient-experience-through-nationwide-digital-services-and-hub-support-for-harrows-branded-eye-care-products/2482530/Harrow announced the nationwide launch of a new digital patient access solution in collaboration with Asembia. This multi-year partnership is designed to expand access to Harrow’s ophthalmic branded products, including Flarex, Ilevro, Maxidex, Maxitrol, Natacyn, Nevanac, Tobradex ST, Verkaz
- Tarsus Appoints Elizabeth Yeu, MD, as Chief Medical Officerhttps://modernod.com/news/tarsus-appoints-elizabeth-yeu-md-as-chief-medical-officer/2482527/Tarsus Pharmaceuticals announced the appointment of Elizabeth Yeu, MD, as chief medical officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus’ chief medical advisor s
- Corxel and Lenz Therapeutics Announce Positive Phase 3 Trial Results for Presbyopia Eye Drop LNZ100 in Chinahttps://modernod.com/news/corxel-pharmaceuticals-and-lenz-therapeutics-announce-positive-phase-3-trial-results-for-presbyopia-eye-drop-lnz100-in-china/2482519/Lenz Therapeutics and its parner Corxel Pharmaceuticals unveiled phase 3 trial results from the China-based JX07001 study, showing that LNZ100, an aceclidine-based eye drop, achieved significant improvement in near vision for presbyopia patients. The study's topline results demonstr